Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
EA-230 by Exponential Biotherapies for Acute Inflammation: Likelihood of Approval
EA-230 is under clinical development by Exponential Biotherapies and currently in Phase II for Acute Inflammation. According to GlobalData, Phase...